Last reviewed · How we verify
triptorelin 0.1
Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.
Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production. Used for Prostate cancer (advanced), Breast cancer (hormone-receptor positive), Endometriosis.
At a glance
| Generic name | triptorelin 0.1 |
|---|---|
| Also known as | decapeptyl 0.1 |
| Sponsor | Chong Qing Reproducive and Genetic Institute |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Reproductive Medicine, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Triptorelin binds to GnRH receptors in the pituitary gland, initially causing a surge in gonadotropin release followed by sustained suppression of LH and FSH through receptor desensitization. This results in profound suppression of testosterone in males and estrogen in females, making it useful for hormone-dependent conditions and reproductive applications.
Approved indications
- Prostate cancer (advanced)
- Breast cancer (hormone-receptor positive)
- Endometriosis
- Uterine fibroids
- Precocious puberty
- Fertility preservation and assisted reproduction
Common side effects
- Hot flashes
- Injection site reactions
- Headache
- Fatigue
- Decreased libido
- Erectile dysfunction
- Gynecomastia
- Bone density loss
Key clinical trials
- Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support (PHASE4)
- Triptorelin for Early Diagnosis of Hypogonadotrophic Hypogonadism (NA)
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)
- Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve (NA)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes. (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- triptorelin 0.1 CI brief — competitive landscape report
- triptorelin 0.1 updates RSS · CI watch RSS
- Chong Qing Reproducive and Genetic Institute portfolio CI